Delving into the Latest Updates on Human umbilical cord mesenchymal stem cells(Jiangsu Topcel-KH Pharmaceutical) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms

MSCs(Jiangsu Topcel-KH Pharmaceutical), Mesenchymal Stem Cells(Jiangsu Topcel-KH Pharmaceutical), Solizmestrocel

+ [1]

Target-

Mechanism

Cell replacements

Therapeutic Areas

Other DiseasesDigestive System Disorders

Active Indication

Perianal fistula due to Crohn's diseaseRadiation proctitisRadiation-induced Rectal Injury

Inactive Indication-

Originator Organization

Jiangsu Tuohong Kangheng Pharmaceutical Co., Ltd.Startup

Active Organization

Jiangsu Tuohong Kangheng Pharmaceutical Co., Ltd.Startup

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Author: Barcena, Allan John R ; Melancon, Marites P. ; Bernardino, Marvin R ; Heralde, Francisco M. ; Heralde, Francisco M ; Bernardino, Marvin R. ; Martin, Benjamin ; Cheng, Jizhong ; Damasco, Jossana A ; San Valentin, Erin Marie D ; Damasco, Jossana A. ; Bouchard, Richard R ; Barcena, Allan John R. ; Bouchard, Richard R. ; Melancon, Marites P ; San Valentin, Erin Marie D. ; Klusman, Carleigh ; Huang, Steven Y. ; Huang, Steven Y ; Canlas, Gino Martin ; Perez, Joy Vanessa D. ; Fowlkes, Natalie ; Perez, Joy Vanessa D

BACKGROUNDMesenchymal stem cells (MSCs) have emerged as novel therapies for supporting arteriovenous fistula (AVF) maturation, and bioresorbable polymeric scaffolds have enabled sustained MSC delivery into maturing AVFs. However, the radiolucency of biopolymeric wraps prevents in vivo monitoring of their integrity and location, hindering long-term preclinical investigations.METHODSWe infused bismuth nanoparticles (BiNPs) into polycaprolactone (PCL) to fabricate an electrospun perivascular wrap capable of MSC delivery and conducive to longitudinal monitoring using conventional imaging. We tested the wraps' effects on the attenuation of markers of neointimal hyperplasia (i.e., endothelial dysfunction, hypoxia, and inflammation), the leading cause of AVF failure, in rats with induced chronic kidney disease (n = 3 per time point) for the following groups: control (no wrap), PCL wrap, PCL with MSCs, PCL-Bi (BiNP-infused wrap), and PCL-Bi with MSCs.RESULTSPhysicochemical characterization and in vitro biocompatibility tests revealed that BiNP infusion did not alter the wrap's non-cytotoxicity toward vascular cells, hemocompatibility, and capacity for MSC loading but facilitated long-term monitoring via micro-computed tomography. After 8 weeks, all treatment groups demonstrated significant improvement in wall-to-lumen ratio on ultrasonography (P < 0.001), neointima-to-lumen ratio on histomorphometry (P < 0.001), and attenuation of neointimal hypoxia on immunohistochemistry (P < 0.05). Compared to non-MSC wraps, MSC-loaded wraps not only attenuated endothelial dysfunction and neointimal inflammation but also reduced hypoxia and inflammation across all vascular layers.CONCLUSIONThese results demonstrate that MSC delivery through a radiopaque polymeric wrap could enhance AVF patency outcomes through the inhibition of multiple pathways inducing AVF failure.

01 Dec 2024·Biochimica et Biophysica Acta (BBA) - Molecular Cell Research

Mitochondrial dynamics and sex-specific responses in the developing rat hippocampus: Effect of perinatal asphyxia and mesenchymal stem cell Secretome treatment

Article

Author: Ezquer, F ; Vega-Vásquez, I. ; García-Navarrete, C. ; Bustamante, D ; Zamorano-Cataldo, M ; Toledo, J. ; Farfán-Troncoso, N ; Urra, F.A. ; Farfán-Troncoso, N. ; Herrera-Marschitz, M ; Ezquer, F. ; Morales, P ; Morales, P. ; Herrera-Marschitz, M. ; Bustamante, D. ; Urra, F A ; García-Navarrete, C ; Toledo, J ; Zamorano-Cataldo, M. ; Vega-Vásquez, I

AIMSPerinatal asphyxia is one of the major causes of neonatal death at birth. Survivors can progress but often suffer from long-term sequelae. We aim to determine the effects of perinatal asphyxia on mitochondrial dynamics and whether mesenchymal stem cell secretome (MSC-S) treatment can alleviate the deleterious effects.MATERIALS AND METHODSAnimals were subjected to 21 min of asphyxia at the time of delivery. MSC-S or vehicle was intranasally administered 2 h post-delivery. Mitochondrial mass (D-loop, qPCR), mitochondrial dynamics proteins (Drp1, Fis1 and OPA1, Western blot), mitochondrial dynamics (TOMM20, Immunofluorescence), as well as mitochondrial membrane potential (ΔΨ_m) (Safranin O) were evaluated at P1 and P7 in the hippocampus.KEY FINDINGSPerinatal asphyxia increased levels of mitochondrial dynamics proteins Drp1 and S-OPA1 at P1 and Fis1 at P7. Mitochondrial density and mass were decreased at P1. Perinatal asphyxia induced sex-specific differences, with increased L-OPA1 in females at P7 and increased mitochondria circularity. In males, asphyxia-exposed animals exhibited a reduced ΔΨ_m at P7. MSC-S treatment normalised levels of mitochondrial dynamics proteins involved in fission.SIGNIFICANCEThis study provides novel insights into the effects of perinatal asphyxia on mitochondrial dynamics in the developing brain and on the therapeutic opportunities provided by mesenchymal stem cell secretome treatment. It also highlights on the relevance of considering sex as a biological variable in perinatal brain injury and therapy development. These findings contribute to the development of targeted, personalised therapies for infants affected by perinatal asphyxia.

01 Dec 2024·Molecular Biology Reports

Effects of mesenchymal stem cells versus curcumin on sonic hedgehog signaling in experimental model of Hepatocellular Carcinoma

Article

Author: Fouad, Hanan ; Sedeak, Ahmed Yahia ; Reyad, Hoda Ramadan ; Faruk, Eman ; Rateb, Enas Ezzat ; Abdel-Tawab, Marwa Sayed ; Doudar, Noha A

BACKGROUNDSonic Hedgehog (SHH) is a fundamental signaling pathway that controls tissue reconstruction, stem cell biology, and differentiation and has a role in gut tissue homeostasis and development. Dysregulation of SHH leads to the development of HCC.METHODS, AND RESULTSThe present study was conducted to compare the effects of mesenchymal stem cells (MSCs) and curcumin on SHH molecular targets in an experimental model of HCC in rats. One hundred rats were divided equally into the following groups: control group, HCC group, HCC group received MSCs, HCC group received curcumin, and HCC group received MSCs and curcumin. Histopathological examinations were performed, and gene expression of SHH signaling target genes (SHH, PTCH1, SMOH, and GLI1) was assessed by real-time PCR in rat liver tissue. Results showed that SHH target genes were significantly upregulated in HCC-untreated rat groups and in MSC-treated groups, with no significant difference between them. Administration of curcumin with or without combined administration of MSCs led to a significant down-regulation of SHH target genes, with no significant differences between both groups. As regards the histopathological examination of liver tissues, both curcumin and MSCs, either through separate use or their combined use, led to a significant restoration of normal liver pathology.CONCLUSIONSIn conclusion, SHH signaling is upregulated in the HCC experimental model. MSCs do not inhibit the upregulated SHH target genes in HCC. Curcumin use with or without MSCs administration led to a significant down-regulation of SHH signaling in HCC and a significant restoration of normal liver pathology.

100 Deals associated with Human umbilical cord mesenchymal stem cells(Jiangsu Topcel-KH Pharmaceutical)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Radiation proctitis	Phase 2	CN	Jiangsu Tuohong Kangheng Pharmaceutical Co., Ltd.Startup	24 May 2024
Perianal fistula due to Crohn's disease	Phase 2	-	Jiangsu Tuohong Kangheng Pharmaceutical Co., Ltd.Startup	30 Nov 2022
Radiation-induced Rectal Injury	Phase 1	CN	Jiangsu Tuohong Kangheng Pharmaceutical Co., Ltd.Startup	21 Sep 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ECCO2016	Not Applicable	Crohn Disease	48	Standard anti-inflammatory therapy with 5-aminosalicylic acid (5-ASA), glucocorticosteroids (GCS), and immunosuppressive (IS)+MSCs	qcswiihlzy(pimcuilbfu) = ulgtdjuizy rlxymlrrwy (hloyesbzda ) View more	Positive	12 Feb 2016
				Therapy anti-cytokine ADA	qcswiihlzy(pimcuilbfu) = ncwzjyqvbr rlxymlrrwy (hloyesbzda ) View more